Novel mechanisms of endothelial Injury in the pathogenesis of ARDS
ARDS发病机制中内皮损伤的新机制
基本信息
- 批准号:10434658
- 负责人:
- 金额:$ 56.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-05-01 至 2024-04-30
- 项目状态:已结题
- 来源:
- 关键词:Acute Lung InjuryAcute Respiratory Distress SyndromeAddressAdherens JunctionAlveolarAnimal ModelAnimalsApoptosisAttenuatedBindingBlood VesselsCASP4 geneCD14 AntigenCD14 geneCXC ChemokinesCXCL12 geneCXCR4 geneCaspaseCellsChemotactic FactorsComplexDataDiagnosisDiseaseEdemaEndothelial CellsEndotheliumEpithelialExtravasationFunctional disorderG-Protein-Coupled ReceptorsGoalsHumanHypoxemiaInfiltrationInflammationInflammatoryInjuryInterventionLeadLiposomesLungMediatingMediator of activation proteinMolecularMusNecrosisOutcomePathogenesisPatientsPharmacologyPhasePlasmaPlayPreventionPrevention approachPrognostic MarkerProteinsPublishingPulmonary EdemaRecombinantsReporterResistanceRoleSamplingSepsisSeveritiesSignal PathwaySignal TransductionSyndromeTherapeuticTransduction GeneUrsidae FamilyVascular Endotheliumbasechemokineearly onseteffective therapyendothelial regenerationendothelial repairepithelial repairepithelial stem cellin vivoinnovationlung injurylung regenerationlung repairmortalitymouse modelnovelnovel strategiesnovel therapeutic interventionplasmid DNApolymicrobial sepsisreceptor couplingrecruitrepairedsepsis induced ARDSsepticsevere injurystemtherapeutic genetherapeutically effectivetranslational potential
项目摘要
Acute respiratory distress syndrome (ARDS) is a complex, multi-factorial syndrome which manifest itself
by leaky lung microvessels, protein rich edema, and intractable hypoxemia. Given that recent studies
from both human and animal studies has demonstrated the key role of microvascular leakage in
determining the outcome of sepsis and ARDS, maintaining the endothelial barrier integrity represents a
novel, effective therapeutic approach for the prevention and treatment of ARDS. However, the molecular
mechanisms mediating endothelial barrier disruption after sepsis remain poorly understood, especially,
little is known about the key molecules and signaling pathways responsible for endothelial barrier
dysfunction resulting in high mortality in ARDS patients. Our Supporting Data show that higher levels of
plasma SDF1 in ARDS patients are positively associated with high mortality. In mice, we observed that
SDF1 treatment augmented sepsis-induced lung injury and mortality, which were attenuated in mice with
inducible EC-specific disruption of Cxcr4 (Cxcr4iEC). Importantly, our mechanistic studies demonstrate
that SDF1 treatment induces endothelial cell pyroptosis leading to severe endothelial barrier dysfunction.
Thus, we hypothesize that elevated plasma SDF1 levels is a prognostic biomarker of severe lung injury
and greater mortality of ARDS patients which is ascribed to SDF1-induced overwhelming endothelial
pyroptosis and resultant severe endothelial barrier dysfunction following sepsis. The proposed studies
will address the following Specific Aims. Studies in Aim 1 will validate circulating SDF1 level as a
prognostic biomarker of ARDS patients and define the signaling pathway mediating SDF1-exaggerated
lung injury and mortality following sepsis challenge. Studies in Aim 2 will delineate the molecular and
cellular mechanisms of SDF1 in augmenting sepsis-induced lung injury through activation of endothelial
pyroptosis and explore the therapeutic potential of inhibiting pyroptosis for treatment of ARDS. With the
data from these comprehensive studies, we will delineate the fundamental mechanisms of endothelial
injury, identify a prognostic biomarker for the severity and mortality of ARDS, and provide novel
therapeutic approaches for effective treatment of ARDS and promotion of survival. Thus, these innovative
mechanistic studies have high translational potential.
急性呼吸窘迫综合征(ARDS)是一种复杂的多因素综合征
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YOU-YANG ZHAO其他文献
YOU-YANG ZHAO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YOU-YANG ZHAO', 18)}}的其他基金
Novel roles of RNA modifications in the pathogenesis of pulmonary vascular remodeling and PAH
RNA修饰在肺血管重塑和PAH发病机制中的新作用
- 批准号:
10540134 - 财政年份:2022
- 资助金额:
$ 56.78万 - 项目类别:
Negative regulators of endothelial regeneration in aging lungs and ARDS
衰老肺和 ARDS 中内皮再生的负调节因子
- 批准号:
10467781 - 财政年份:2022
- 资助金额:
$ 56.78万 - 项目类别:
Negative regulators of endothelial regeneration in aging lungs and ARDS
衰老肺和 ARDS 中内皮再生的负调节因子
- 批准号:
10629328 - 财政年份:2022
- 资助金额:
$ 56.78万 - 项目类别:
Novel mechanisms of endothelial Injury in the pathogenesis of ARDS
ARDS发病机制中内皮损伤的新机制
- 批准号:
10618326 - 财政年份:2020
- 资助金额:
$ 56.78万 - 项目类别:
Targeting Smooth Muscle Progenitor Cells for Treatment of Pulmonary Arterial Hypertension
靶向平滑肌祖细胞治疗肺动脉高压
- 批准号:
10189689 - 财政年份:2018
- 资助金额:
$ 56.78万 - 项目类别:
Novel mechanisms of obliterative pulmonary vascular remodeling and severe pulmonary arterial hypertension
闭塞性肺血管重塑和严重肺动脉高压的新机制
- 批准号:
10470871 - 财政年份:2016
- 资助金额:
$ 56.78万 - 项目类别:
Novel mechanisms of obliterative pulmonary vascular remodeling and severe pulmonary arterial hypertension
闭塞性肺血管重塑和严重肺动脉高压的新机制
- 批准号:
10316765 - 财政年份:2016
- 资助金额:
$ 56.78万 - 项目类别:
Novel mechanisms of obliterative pulmonary vascular remodeling and severe pulmonary arterial hypertension
闭塞性肺血管重塑和严重肺动脉高压的新机制
- 批准号:
10677597 - 财政年份:2016
- 资助金额:
$ 56.78万 - 项目类别:
Novel Signalings and Molecular Targets of Endothelial Regeneration in Aging Lung
衰老肺内皮再生的新信号传导和分子靶点
- 批准号:
8909182 - 财政年份:2014
- 资助金额:
$ 56.78万 - 项目类别:
Novel Signalings and Molecular Targets of Endothelial Regeneration in Aging Lung
衰老肺内皮再生的新信号传导和分子靶点
- 批准号:
9307973 - 财政年份:2014
- 资助金额:
$ 56.78万 - 项目类别:
相似海外基金
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 56.78万 - 项目类别:
Research Grant
The Association Between Aging, Inflammation, and Clinical Outcomes in Acute Respiratory Distress Syndrome
衰老、炎症与急性呼吸窘迫综合征临床结果之间的关联
- 批准号:
10722669 - 财政年份:2023
- 资助金额:
$ 56.78万 - 项目类别:
Sedatives Pharmacology in Acute Respiratory Distress Syndrome- SPA
急性呼吸窘迫综合征中的镇静药理学 - SPA
- 批准号:
491387 - 财政年份:2023
- 资助金额:
$ 56.78万 - 项目类别:
Fellowship Programs
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome
基于新机制的 TREM-1 疗法治疗急性呼吸窘迫综合征
- 批准号:
10678788 - 财政年份:2023
- 资助金额:
$ 56.78万 - 项目类别:
Great Lakes Clinical Center of the Acute Respiratory Distress Syndrome, Pneumonia and Sepsis (APS) Consortium
急性呼吸窘迫综合征、肺炎和败血症 (APS) 联盟五大湖临床中心
- 批准号:
10646578 - 财政年份:2023
- 资助金额:
$ 56.78万 - 项目类别:
Effect of ADAMTS13 on pathogenesis of acute respiratory distress syndrome
ADAMTS13 对急性呼吸窘迫综合征发病机制的影响
- 批准号:
23K08447 - 财政年份:2023
- 资助金额:
$ 56.78万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)
一种新型合成生物学衍生的微生物疗法,可治疗病毒引起的急性呼吸窘迫综合征(ARDS)
- 批准号:
10601865 - 财政年份:2023
- 资助金额:
$ 56.78万 - 项目类别:
Development of drug therapy targeting ferroptosis, iron-dependent cell death for acute respiratory distress syndrome.
开发针对铁死亡(急性呼吸窘迫综合征的铁依赖性细胞死亡)的药物疗法。
- 批准号:
23K08360 - 财政年份:2023
- 资助金额:
$ 56.78万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Sustainable Implementation of Prone Positioning for the Acute Respiratory Distress Syndrome
持续实施俯卧位治疗急性呼吸窘迫综合征
- 批准号:
10722194 - 财政年份:2023
- 资助金额:
$ 56.78万 - 项目类别:
Point-of-care system to assess the risk of trauma-induced acute respiratory distress syndrome
用于评估创伤引起的急性呼吸窘迫综合征风险的护理点系统
- 批准号:
10594793 - 财政年份:2023
- 资助金额:
$ 56.78万 - 项目类别:














{{item.name}}会员




